key: cord-0933061-rixdcgbc
authors: Li, Yang; Xu, Zhaowei; Lei, Qing; Lai, Dan-yun; Hou, Hongyan; Jiang, He-wei; Zheng, Yun-xiao; Wang, Xue-ning; Wu, Jiaoxiang; Ma, Ming-liang; Zhang, Bo; Chen, Hong; Yu, Caizheng; Xue, Jun-biao; Zhang, Hai-nan; Qi, Huan; Guo, Shu-juan; Zhang, Yandi; Lin, Xiaosong; Yao, Zongjie; Sheng, Huiming; Sun, Ziyong; Wang, Feng; Fan, Xionglin; Tao, Sheng-ce
title: Antibody landscape against SARS-CoV-2 proteome reveals significant differences between non-structural/ accessory proteins and structural proteins
date: 2021-06-26
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109391
sha: 60f25aaba58c03f2a59b5e737549e8a2c15303b0
doc_id: 933061
cord_uid: rixdcgbc

The immunogenicity of SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. Here we collect 2,360 COVID-19 sera and 601 control sera. We analyze these sera on a protein microarray with 20 proteins of SARS-CoV-2, built an antibody response landscape for IgG and IgM. Non-structural proteins and accessory proteins NSP1, NSP7, NSP8, RdRp, ORF3b and ORF9b elicit prevalent IgG responses. The IgG patterns and dynamic of non-structural/ accessory proteins are different from that of S and N protein. The IgG responses against these 6 proteins are associated with disease severity and clinical outcome and declined sharply about 20 days after symptom onset. In non-survivors, sharp decrease of IgG antibodies against S1 and N protein before death is observed. The global antibody responses to non-structural/ accessory proteins revealed here may facilitate deeper understanding of SARS-CoV-2 immunology.

). According to the 106 severity and clinical outcome, the patients were divided into three groups, i. e., Non-severe 107 patients, all of whom were recovered, severe but survived patients and non-survivors.

Statistical comparison among these three groups enables us to investigate the features either 109 related to the severity for survivors or to the outcome under similar severity ( identified a set of clinical and laboratory parameters which are highly related to severity or 116 outcome , such as lymphopenia, increased CRP (C reaction protein) and factors associated 117 with blood coagulation, cardiac injury, liver injury and kidney injury. Most of these factors 118 are associated both with severity and outcome, while some are likely associated either with 119 severity or outcome. For instance, thrombocytopenia and some kidney injury related factors 120 are more common in non-survivors as compared to the other two groups, while most liver 121 injury related factors are only associated with severity but not outcome.

Several non-structural and accessory proteins elicit highly prevalent antibody responses 124 Previously, we have constructed a SARS-CoV-2 proteome microarray ( Figure S1a , b, Table   125 S2) and screened a small cohort of convalescent patients . Here, we aimed 126 to systematically analyze the immune responses and its dynamic change against 127 SARS-CoV-2 proteins with a much larger cohort of samples. In total, we collected 2,360 sera S1). All of these sera were analyzed on the SARS-CoV-2 protein microarray. To acquire 130 high-quality data for the microarray experiments, we prepared a positive control by mixing 50 131 randomly selected COVID-19 sera. This control was then probed on each microarray to 132 assess and normalize the data. It turns out that high reproducibility is achieved in our assay 133 ( Figure S1c, d) . To construct the antibody response landscape against the whole proteome, a 134 subset of the sera collection was selected. Since seroprevalence would gradually increase to 135 plateau till about 2 weeks after symptom onset (Long et al., 2020a) , the samples collected 136 within 14 days were excluded. For the patients with more than one samples, the serum 137 collected at the earliest time point after two weeks of symptom onset was selected. A total of 138 756 serum samples were selected to construct the landscape (Figure 1) . Immune response 139 frequency was calculated for each protein with the cutoff value set by mean + 2 x SD of the 140 control group. Except for S1 and N, which are known of highly antigenic, we found that 141 several non-structural and accessory proteins elicited prevalent antibody responses, especially 142 for IgG, including NSP1, NSP7, NSP8, RdRp, ORF3b and ORF9b, for which the positive 143 rates are 38%, 48.4%, 27.9%, 30.3%, 52.1% and 28%, respectively. Although the IgM 144 responses were high in some cases, the overall responses are much lower than that of IgG. We 145 then decided to focus on IgG for in-depth analysis.

The IgG pattern of Non-structural and accessory proteins is distinct from that of S1 and 148 N protein

We next asked whether the IgG responses to these proteins are associated with each other. We 150 firstly chose NSP7 as a reference. The samples were divided into two groups depending on 151 positive or negative of NSP7 IgG. Positive rates of the rest proteins were calculated for the 152 two groups. Unexpectedly, for all the non-structural and accessory proteins, except for 153 ORF3a, ORF6 and ORF7a which barely elicit antibodies, the positive rates in NSP7-IgG 154 positive group was significantly higher than that in NSP7-IgG negative group, demonstrating 155 high correlations (Figure 2a) . Interestingly, there is no obvious difference for the IgG 156 responses of S1 and N. Similar observations were shown for NSP1, RaRp and ORF3b as proteins were calculated and then clustered. The proteins with positive rate less than 10% 167 were not included duo to statistical limit. (Figure 2c ).

Consistently, the S and N proteins have lower correlations with the 169 non-structural/accessory proteins, while the non-structural/accessory proteins were clustered 170 together. In addition, several sub-clusters were shown among the non-structural/accessory 171 proteins. Interestingly, NSP8 and RdRp have a high correlation (Figure 2d) . It is known that 172 RdRp, NSP8 and NSP7 could form a tight complex (Gao et al., Yin et al., 2020) , which 173 might contribute to the high correlation. However, the correlation between NSP8 and NSP7 is 174 less significant (Figure 2c, e) . The structure of the complex shows NSP7 physically connect 175 to RdRp and NSP8, but with most of the protein surface blocked (Figure 2f) , while NSP8 and

RdRp are more accessible. However, NSP7 elicits antibody in a higher rate (Figure 1a other SARS-CoV-2 proteins, especially non-structural and accessory proteins haven't been 191 revealed yet. As described above, we divided the patient population into three groups, i.e.

Non-severe, severe survivors and severe non-survivors. Two statistical methods were applied 193 to assess the correlations. One is to analyze the positive rate of IgG against each protein, and 194 the other is to compare the signal intensity distribution among groups (Figure 3 ). For N 195 protein, no significant difference among the three groups while for S1 protein, only 196 statistically significant difference was observed between severe and non-severe groups 197 (Figure 3 a, b) . In contrast, the non-structural/accessory proteins, that with high positive 198 rates/ signal intensities, are more significantly correlated with severity. It is worth noting that 199 for the 6 non-structural and accessory proteins, both the positive rates and signal intensities 200 are significantly higher in more severe groups (Figure 3 c-h) . These results indicate that the disease severity, and may could serve as a better predictor of COVID-19 severity than that of 203 S1 and N proteins.

We next analyzed the correlation between antibody response and clinical parameter. The 205 clinical parameters, which have statistical correlations with IgG against S1, N, NSP7, NSP8,

RdRp, ORF3b and ORF9b, were determined (Table S3, Figure S4 ). All of these parameters 207 are related with severity, suggesting severity is a major factor and confounder that contribute 208 to the correlations. Interestingly, thrombocytopenia, is related with clinical outcome but not 209 severity (Table 1) , is significantly correlated with NSP7 and ORF3b but not S1 and N, further We next analyzed the dynamic of IgG responses for the 6 non-structural/accessory proteins.

proteins reached plateau in all the three groups at about 20 days after the symptom onset, and 240 then decreased rapidly for all the three groups (Figure 5a, 5b) , this is largely different from 241 S1 and N protein (Figure 4) . We next selected NSP7 IgG as an example for further analysis 242 and depicted the change for each patient (Figure 5c-e) . Continuous and dramatic decline of 243 IgG against NSP7 for most patients were observed (Figure 5d, 5e) . These results imply the B 244 cells that producing IgG antibodies against non-structural/accessory proteins might be 245 short-lived, and/ or the underlying mechanism of generating IgG antibodies against 246 non-structural/accessory proteins may differ from that of S1 and N proteins.

In this study, we profiled 2,360 sera from 783 patients with COVID-19 and 601 control sera 250 using a SARS-CoV-2 proteome microarray. We found that 6 non-structural/accessory been reported to be able to elicit strong antibody response (Hachim et al., 2020) . Some of 277 these missing proteins will be added when we update the microarray.

Comparison of the IgG responses among the antigenic proteins revealed the possibility that 279 the generation of antibodies against the non-structural/accessory proteins are not independent 280 with each other, which means for one patient that positive for one protein tend to has a 281 significant chance to be positive for other proteins. This is expected since these proteins may 282 be simultaneously exposed to or not to the immune system. Interestingly, high correlations 283 were shown between some particular proteins, likely revealing the high associations of these 284 proteins during infection and disease progression. For instance, it is known that RdRp, NSP7 285 and NSP8 form a complex for replication and translation of the viral genome.

Correspondingly, high correlations of their elicited antibody responses, particular for NSP8 287 and RdRp, were observed. We also observed high correlations between NSP2 and NSP16, 288 suggesting the two proteins might associate in vivo.

The function of the antibodies to non-structural/accessory proteins are still largely 290 unknown, our results reveal that the antibody levels are more associated with disease severity, 291 particularly with the final outcome. These findings imply that the antibodies against 292 non-structural/accessory proteins may play more important roles, thus worth further and 293 in-depth investigation. One concern about the antibody against S protein is the possible ADE 

In contrast to the antibody levels of S and N protein are stable for survivors, we observed 327 the overall antibody levels start to decline in non-survivors at about ten days before death. 

Correlations of the IgG responses against NSP2 and NSP16. For a-b, error bar was given as 380 the 95% confidential interval. P-value was calculated by two-sided χ 2 test. *, P < 0.05, **, P < 381 0.01, ***, P < 0.001, ****, P < 0.0001, n. s., not significant. 386 RdRp (f) ORF3b (g) and ORF9b (h). For positive rate analysis, error bar was given as the 95% 387 confidential interval. P-value was calculated by two-sided χ 2 test. *, P < 0.05, **, P < 0.01, 388 ***, P < 0.001, ****, P < 0.0001, n. s., not significant. For signal intensity analysis, the 389 middle line was median value; the upper and lower hinges were the values of 75% and 25% 390 percentile. P-value was calculated by two-sided t test. were averaged if there were more than one sample during each three-day. P-value was 401 calculated by two-sided t test between the indicated group and the first group (0 -2 days). *, P 402 < 0.05, **, P < 0.01, ***, P < 0.001, n. s., not significant. 

Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (80-. )

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

Isolation and characterization of a bat SARS-like coronavirus that uses the 573 ACE2 receptor

A SARS-CoV-2 protein interaction map reveals targets 576 for drug repurposing

Humoral Immune 579 Response to SARS-CoV-2 in Iceland

SARS corona virus peptides 581 recognized by antibodies in the sera of convalescent cases

ORF8 and ORF3b antibodies are accurate 584 serological markers of early and late SARS-CoV-2 infection

Temporal dynamics in viral shedding and transmissibility of COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and 590 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Rapid Decay of Anti-SARS-CoV

Antibodies in Persons with Mild Covid-19

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting 599 TOM70

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Neutralizing Antibodies against SARS-CoV-2 and Other 604

Pheatmap: Pretty Heatmaps

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose 608

Activity Is Increased by a Naturally Occurring Elongation Variant

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Antibody dynamics to 613 SARS-CoV-2 in asymptomatic COVID-19 infections

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing 616 SARS-CoV-2 Pathogenesis

Longitudinal 618 serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung 619 adenocarcinoma

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute 622 SARS-CoV infection

Antibody responses to SARS-CoV-2 in patients with COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

The generation of 632 antibody-secreting plasma cells

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities

The COVID-19 Cytokine 637 Storm; What We Know So Far

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and 640 correlates of severity

Structural basis for translational shutdown and 643 immune evasion by the Nsp1 protein of SARS-CoV-2. Science (80-. )

Immunology of COVID-19: Current State of the Science

SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino 649 acid resolution

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating 655 in China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients 658

With Coronavirus Disease

A new coronavirus associated with human respiratory disease in China

studies based on cellular and structural biology analysis

Structural basis for the recognition 666 of SARS-CoV-2 by full-length human ACE2

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 669 by remdesivir

A pneumonia outbreak associated with a new coronavirus of probable bat origin. 672